Replimune [REPL] vs Vertex [VRTX] Detailed Stock Comparison
Replimune
NASDAQ
Loading...
Vertex
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Replimune wins in 6 metrics, Vertex wins in 8 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Replimune | Vertex | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -2.06 | 32.82 | Replimune |
| Price-to-Book Ratio | 1.17 | 7.05 | Replimune |
| Debt-to-Equity Ratio | 18.32 | 8.89 | Vertex |
| PEG Ratio | -2.35 | 25.16 | Replimune |
| EV/EBITDA | -0.31 | 24.22 | Replimune |
| Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
| Operating Margin (TTM) | 0.00% | 38.93% | Vertex |
| EBITDA Margin (TTM) | N/A | 38.93% | N/A |
| Return on Equity | -62.58% | 22.77% | Vertex |
| Return on Assets (TTM) | -31.26% | 13.09% | Vertex |
| Free Cash Flow (TTM) | $-198.94M | $-978.00M | Replimune |
| 1-Year Return | -44.78% | -21.75% | Vertex |
| Price-to-Sales Ratio (TTM) | N/A | 10.62 | N/A |
| Enterprise Value | $79.55M | $116.19B | Vertex |
| EV/Revenue Ratio | N/A | 10.18 | N/A |
| Gross Profit Margin (TTM) | N/A | 86.90% | N/A |
| Revenue per Share (TTM) | $0 | $44 | Vertex |
| Earnings per Share (Diluted) | $-3.07 | $-3.83 | Replimune |
| Beta (Stock Volatility) | 0.67 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Replimune vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Replimune | -3.47% | -30.39% | -43.36% | -31.92% | -59.68% | -57.88% |
| Vertex | -2.42% | -20.68% | -21.40% | -14.68% | -22.01% | -9.67% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Replimune | -44.78% | -73.90% | -77.34% | -65.11% | -65.11% | -65.11% |
| Vertex | -21.75% | 24.45% | 37.13% | 167.78% | 912.82% | 2,065.03% |
Performance & Financial Health Analysis: Replimune vs Vertex
| Metric | REPL | VRTX |
|---|---|---|
| Market Information | ||
| Market Cap | $491.74M | $121.28B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 35,582,270 | 1,390,330 |
| 90 Day Avg. Volume | 16,166,717 | 1,229,373 |
| Last Close | $5.29 | $366.54 |
| 52 Week Range | $2.68 - $17.00 | $364.66 - $519.88 |
| % from 52W High | -68.88% | -29.50% |
| All-Time High | $54.85 (Nov 16, 2020) | $519.88 (Nov 04, 2024) |
| % from All-Time High | -90.36% | -29.50% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.12% |
| Quarterly Earnings Growth | N/A | 0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.32% |
| Operating Margin (TTM) | 0.00% | 0.39% |
| Return on Equity (TTM) | -0.63% | 0.23% |
| Debt to Equity (MRQ) | 18.32 | 8.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $5.40 | $67.01 |
| Cash per Share (MRQ) | $6.28 | $24.90 |
| Operating Cash Flow (TTM) | $-192,250,000 | $-562,900,000 |
| Levered Free Cash Flow (TTM) | $-110,311,872 | $-438,500,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Replimune vs Vertex
| Metric | REPL | VRTX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -2.06 | 32.82 |
| Forward P/E | -2.35 | 25.16 |
| PEG Ratio | -2.35 | 25.16 |
| Price to Sales (TTM) | N/A | 10.62 |
| Price to Book (MRQ) | 1.17 | 7.05 |
| Market Capitalization | ||
| Market Capitalization | $491.74M | $121.28B |
| Enterprise Value | $79.55M | $116.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 10.18 |
| Enterprise to EBITDA | -0.31 | 24.22 |
| Risk & Other Metrics | ||
| Beta | 0.67 | N/A |
| Book Value per Share (MRQ) | $5.40 | $67.01 |
Financial Statements Comparison: Replimune vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | REPL | VRTX |
|---|---|---|
| Revenue/Sales | $0 | $2.96B |
| Cost of Goods Sold | N/A | $407.50M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $53.98M | $978.40M |
| Operating Income (EBIT) | $-78.78M | $1.15B |
| EBITDA | $-77.28M | $1.34B |
| Pre-Tax Income | $-74.24M | $1.28B |
| Income Tax | $-107,000 | $250.10M |
| Net Income (Profit) | $-74.13M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | REPL | VRTX |
|---|---|---|
| Cash & Equivalents | $111.12M | $4.67B |
| Total Current Assets | $495.88M | $10.01B |
| Total Current Liabilities | $62.36M | $3.78B |
| Long-Term Debt | $72.18M | $1.65B |
| Total Shareholders Equity | $415.84M | $16.50B |
| Retained Earnings | $-948.58M | $10.25B |
| Property, Plant & Equipment | $38.81M | $2.63B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | REPL | VRTX |
|---|---|---|
| Operating Cash Flow | $-59.63M | $404.90M |
| Capital Expenditures | $-1.13M | $-40.70M |
| Free Cash Flow | $-54.87M | $778.20M |
| Debt Repayment | $-163,000 | $-1.30M |
| Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
| Metric | REPL | VRTX |
|---|---|---|
| Shares Short | 8.02M | 4.19M |
| Short Ratio | 4.98 | 3.34 |
| Short % of Float | 0.19% | 0.02% |
| Average Daily Volume (10 Day) | 35,582,270 | 1,390,330 |
| Average Daily Volume (90 Day) | 16,166,717 | 1,229,373 |
| Shares Outstanding | 77.01M | 256.94M |
| Float Shares | 49.03M | 255.58M |
| % Held by Insiders | 0.02% | 0.00% |
| % Held by Institutions | 1.07% | 0.98% |
Dividend Analysis & Yield Comparison: Replimune vs Vertex
| Metric | REPL | VRTX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |